GlassScriptPhysician profile
Seemeen Hassan
NPI 1619264033
$3,346.88
in general payments reported to CMS, 2019-2025
11 companies · $490 in 2025
The $490 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,190 · 2024: $1,668 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,243 · Food and Beverage: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,242.97 |
| Food and Beverage | $1,103.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,868.24 | 2023-2025 | Resolution 360 Clip, General - Hemostasis |
| Abbvie INC. | $190.99 | 2024-2025 | |
| Genzyme Corporation | $75.65 | 2025 | |
| Conmed Corporation | $45.45 | 2024 | Conmed Biliary |
| Madrigal Pharmaceuticals | $39.97 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $25.66 | 2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $24.60 | 2025 | Iqirvo |
| Lilly USA, LLC | $20.86 | 2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.39 | 2024 | Xifaxan |
| Exact Sciences Corporation | $18.30 | 2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $16.77 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seemeen Hassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.